Commentary: Antimicrobial resistance trends of ESKAPEE pathogens isolated from intensive care unit patients at a tertiary care hospital in Mogadishu, Somalia: a retrospective study (2020–2024)
Frontiers in Microbiology · 11.11.2026 · 17
DOI: 10.3389/fmicb.2026.2021086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 11.11.2026. Verfasst von Abdisalan Abdikarin Mohamed und 3 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Intensivpflege
Abstract (Originalsprache)
We read with interest the retrospective study by Ibrahim and colleagues describing ESKAPEE resistance patterns among intensive care unit patients in Mogadishu, Somalia [1]. The study contributes valuable local microbiological evidence. Its implications for empirical treatment and surveillance would be strengthened by clarification of laboratory validation, reconciliation of the multidrug resistance (MDR) estimates, and more explicit reporting of uncertainty in annual resistance proportions. These issues concern how the findings should be interpreted rather than whether local surveillance is needed.First, the methods describe Kirby-Bauer disk diffusion, including vancomycin and colistin disks, but do not clearly describe organism-antibiotic-specific minimum inhibitory concentration (MIC) confirmation [1]. CDC guidance does not recommend disk diffusion for vancomycin susceptibility testing in Staphylococcus aureus and advises verification of suspected intermediate or resistant results through repeat identification and a validated MIC method [2]. For colistin, the joint CLSI-EUCAST recommendations identify broth microdilution as the reference method and do not recommend disk diffusion [3]. The authors acknowledge that vancomycin-resistant S. aureus was not systematically assessed, yet report approximately 6% vancomycin resistance in 2024. They also report low colistin resistance in Klebsiella pneumoniae [1]. Were these results obtained or confirmed using appropriate MIC methods? Reporting the methods, MIC values, and interpretive criteria would help readers assess whether these findings represent validated resistance phenotypes. CLSI M100 and EUCAST breakpoint tables provide organism-antibiotic-specific interpretive criteria [4,5]. The authors should specify the standard and version applied in each study year and whether historical results were reinterpreted using a common version. Screening results alone should not be presented as MIC-confirmed vancomycin-intermediate or vancomycin-resistant S. aureus (VISA or VRSA).Second, the MDR estimates require reconciliation. The abstract reports MDR in 85% of Acinetobacter baumannii and 78% of K. pneumoniae isolates, whereas Table 4 reports 150/194 (77.3%) and 70/144 (48.6%), respectively [1]. It remains unclear whether different analytical populations or denominators explain these differences. Magiorakos and colleagues define MDR by acquired non-susceptibility affecting at least one drug within each of three or more antimicrobial categories [6]. Clarifying how the study's stated definition was operationalized, including the categories assessed and handling of intermediate results and incomplete testing, would aid interpretation. Because these estimates underpin the characterization of the MDR burden, clarification of the applicable denominators and consistency between the abstract and detailed results are important. The authors could also explain how missing MDR classifications were handled and state the number of isolates included in each analysis.Third, annual percentages need explicit testing denominators and uncertainty estimates. The authors appropriately acknowledge sparse samples and missing organism-year observations [1]. Nevertheless, Table 3 reports 100% Enterobacter resistance in 2023 for several agents, each based on one resistant isolate, implying one tested isolate. Such a proportion provides limited evidence of a population-level temporal shift. Reporting resistant/tested counts and appropriate 95% confidence intervals for each organism-antibiotic-year combination would make this uncertainty visible. Clarification of repeat-isolate handling is also needed: was analysis restricted to the first isolate per patient and organism, or were repeat episodes included? CLSI M39 distinguishes routine antibiogram preparation from analyses intended to detect emerging resistance; the chosen approach should match the surveillance objective [7]. In addition, the October 2024 endpoint limits direct comparison of annual isolate counts, although an incomplete year does not inherently bias resistance proportions. Changes in testing coverage, breakpoints, and specimen mix should be considered when interpreting annual differences.These clarifications would strengthen confidence in the study's interpretation and support its use in locally informed stewardship. We encourage the authors to reconcile the MDR estimates, document appropriate confirmation of the relevant susceptibility results, and provide transparent denominators and uncertainty estimates. This would help clinicians distinguish preliminary surveillance signals from findings sufficiently supported to inform empirical treatment protocols.
Zitieren
APA
Mohamed, A. A., Mohamed, A. O., Abdi, A. M., & Samaan, A. H. (2026). Commentary: Antimicrobial resistance trends of ESKAPEE pathogens isolated from intensive care unit patients at a tertiary care hospital in Mogadishu, Somalia: a retrospective study (2020–2024). Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.2021086
Vancouver
Mohamed AA, Mohamed AO, Abdi AM, Samaan AH. Commentary: Antimicrobial resistance trends of ESKAPEE pathogens isolated from intensive care unit patients at a tertiary care hospital in Mogadishu, Somalia: a retrospective study (2020–2024). Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.2021086
BibTeX
@article{Mohamed2026,
author = {Mohamed, Abdisalan Abdikarin and Mohamed, Abdullahi Osman and Abdi, Abdinasir Mohamed and Samaan, Abshir Hassan},
title = {Commentary: Antimicrobial resistance trends of ESKAPEE pathogens isolated from intensive care unit patients at a tertiary care hospital in Mogadishu, Somalia: a retrospective study (2020–2024)},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.2021086}
}
EUVIMED